Albumin (Human) Market Size, Share, Growth, and Industry Analysis, By Type ( Injection,Freeze-dried Injection ), By Application ( Liver Diseases,Kidney Diseases,Neoplasm ), Regional Insights and Forecast to 2035

Albumin (Human) Market Overview

Global Albumin (Human) market size is anticipated to be worth USD 5762.18 million in 2026 and is expected to reach USD 8693.21 million by 2035 at a CAGR of 4.7%.

The Albumin (Human) Market is driven by the increasing demand for plasma-derived therapies, with over 60 million liters of plasma collected globally in 2023, of which approximately 35% is utilized for albumin production. Albumin (Human) Market Analysis shows that human albumin accounts for nearly 55% of plasma protein usage in therapeutic applications. The Albumin (Human) Market Size is influenced by rising chronic disease prevalence, with liver disorders affecting over 2 million patients annually worldwide. Albumin (Human) Market Trends indicate that more than 70% of albumin is administered in hospitals, while 30% is used in outpatient settings, supporting Albumin (Human) Market Growth and Albumin (Human) Market Outlook.

In the United States, the Albumin (Human) Market demonstrates strong demand, with over 25 million plasma donations recorded annually, contributing to nearly 40% of global plasma supply. Albumin (Human) Industry Analysis highlights that approximately 65% of albumin usage in the U.S. is linked to critical care treatments, including trauma and burn management. Around 1.5 million liver disease cases annually contribute significantly to Albumin (Human) Market Share in the country. Albumin (Human) Market Research Report indicates that over 80% of hospitals in the U.S. stock albumin products, reinforcing Albumin (Human) Market Opportunities and Albumin (Human) Market Insights.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Over 68% demand growth is driven by chronic diseases, with 52% linked to liver disorders, 47% to kidney complications, and 39% to critical care applications, highlighting strong Albumin (Human) Market Growth and Albumin (Human) Market Trends.
• Major Market Restraint: Approximately 42% of supply limitations are linked to plasma shortages, 36% to high processing costs, and 28% to regulatory constraints, affecting Albumin (Human) Market Size and Albumin (Human) Market Outlook globally.
• Emerging Trends: Nearly 57% of manufacturers are investing in recombinant albumin technologies, while 49% focus on advanced purification techniques and 44% on automation, shaping Albumin (Human) Market Trends and Albumin (Human) Industry Analysis.
• Regional Leadership: North America holds approximately 38% market share, followed by Europe at 29%, Asia-Pacific at 25%, and others at 8%, reflecting Albumin (Human) Market Share and Albumin (Human) Market Insights.
• Competitive Landscape: Top 5 players control nearly 62% of the global market, with leading firms individually holding between 12% and 18%, indicating a moderately consolidated Albumin (Human) Industry Report structure.
• Market Segmentation: Injection forms account for approximately 64% of usage, while freeze-dried variants hold 36%, with liver disease applications contributing 48%, kidney diseases 27%, and neoplasm treatments 25%.
• Recent Development: Around 53% of companies expanded plasma collection centers between 2023 and 2025, while 46% invested in R&D and 41% launched new albumin formulations, boosting Albumin (Human) Market Opportunities.

Albumin (Human) Market Latest Trends

Albumin (Human) Market Trends are evolving rapidly due to increasing demand for plasma-derived therapies, with over 70% of albumin used in intensive care units globally. Albumin (Human) Market Analysis indicates that more than 45% of hospitals prefer albumin over synthetic colloids, driven by better clinical outcomes. Albumin (Human) Market Research Report highlights that approximately 58% of global manufacturers are investing in advanced fractionation technologies to improve yield efficiency by 20%.

Additionally, Albumin (Human) Market Growth is supported by rising applications in drug formulation, where nearly 30% of albumin production is used as a stabilizer in vaccines and biologics. Albumin (Human) Market Insights reveal that demand in oncology-related treatments has increased by 35%, while usage in liver disease treatments accounts for nearly 48% of total consumption. Albumin (Human) Market Outlook also shows that plasma collection infrastructure has expanded by over 40% globally in the last 5 years, strengthening supply chains and enhancing Albumin (Human) Market Opportunities.

Albumin (Human) Market Dynamics

DRIVER

"Rising demand for plasma-derived therapeutics"

The Albumin (Human) Market is significantly driven by the increasing prevalence of chronic diseases, with over 2.4 billion individuals globally affected by chronic conditions. Albumin (Human) Market Analysis shows that liver diseases account for nearly 48% of albumin usage, while critical care applications represent 32%. The growing number of surgeries, exceeding 310 million annually worldwide, further boosts albumin demand in perioperative care. Albumin (Human) Market Trends indicate that ICU admissions requiring albumin therapy have increased by 28% over the last decade, reinforcing Albumin (Human) Market Growth and Albumin (Human) Market Size expansion.

RESTRAINT

"Limited plasma supply and high processing complexity"

One of the major restraints in the Albumin (Human) Market is the limited availability of plasma, with only 3%–5% of eligible donors contributing regularly. Albumin (Human) Industry Analysis highlights that plasma fractionation requires 6–9 months of processing time, with approximately 25% material loss during purification. Regulatory compliance affects nearly 35% of manufacturers, delaying production timelines. Albumin (Human) Market Insights show that high operational costs impact about 40% of small-scale producers, restricting market entry and affecting Albumin (Human) Market Share.

OPPORTUNITY

"Expansion in emerging healthcare markets"

Emerging economies contribute significantly to Albumin (Human) Market Opportunities, with Asia-Pacific accounting for 25% of global demand and growing hospital infrastructure by over 50% in the last decade. Albumin (Human) Market Research Report indicates that plasma collection centers in developing countries have increased by 45%, enhancing supply capabilities. Rising healthcare expenditure in these regions supports Albumin (Human) Market Growth, with approximately 60% of new hospitals integrating albumin therapies. This trend strengthens Albumin (Human) Market Outlook and global expansion.

CHALLENGE

"Stringent regulatory and safety requirements"

The Albumin (Human) Market faces challenges related to stringent regulatory frameworks, with over 70% of production facilities requiring multi-stage approvals. Albumin (Human) Market Analysis shows that safety testing procedures account for nearly 30% of production timelines, delaying product availability. Additionally, 18% of batches face quality rejection due to contamination risks, impacting supply consistency. Albumin (Human) Industry Report highlights that compliance costs affect approximately 38% of manufacturers, creating barriers to scalability and affecting Albumin (Human) Market Trends.

Albumin (Human) Market Segmentation

Download Free Sample to learn more about this report.

The Albumin (Human) Market is segmented by type and application, with injection forms accounting for 64% of total usage, while freeze-dried injections hold 36%. By application, liver diseases dominate with 48% share, followed by kidney diseases at 27%, and neoplasm treatments at 25%. Albumin (Human) Market Insights indicate that hospital usage represents over 70% of demand, while clinics and research institutions contribute 30%, supporting Albumin (Human) Market Growth and Albumin (Human) Market Outlook.

BY TYPE

Injection: Injection-based albumin dominates the Albumin (Human) Market Share with approximately 64% usage, primarily due to immediate therapeutic action. Over 75% of ICU patients requiring plasma expanders receive injectable albumin, highlighting its clinical importance. Albumin (Human) Market Analysis shows that injectable forms are used in 90% of emergency treatments, including trauma and burns. Additionally, demand for injections has increased by 35% over the past decade, supporting Albumin (Human) Market Trends and Albumin (Human) Market Growth.

Freeze-dried Injection: Freeze-dried albumin accounts for nearly 36% of the Albumin (Human) Market Size, offering advantages such as extended shelf life of up to 24 months. Approximately 40% of rural healthcare facilities prefer freeze-dried variants due to easier storage and transportation. Albumin (Human) Market Research Report indicates that freeze-dried formulations reduce wastage by 20%, making them suitable for developing regions. Increasing adoption in military and emergency kits further strengthens Albumin (Human) Market Opportunities.

BY APPLICATION

Liver Diseases: Liver diseases dominate the Albumin (Human) Market Share with approximately 48% of total consumption, as albumin is essential in managing conditions such as cirrhosis, ascites, and hepatic failure. Globally, more than 2 million deaths annually are attributed to liver diseases, while over 30 million patients in developed regions alone require albumin-based therapies. Albumin (Human) Market Analysis shows that nearly 68% of cirrhosis patients receive albumin infusions during treatment, particularly for complications like spontaneous bacterial peritonitis. Additionally, liver-related hospital admissions have increased by approximately 22% over the past decade, further driving Albumin (Human) Market Growth.

Kidney Diseases: Kidney disease applications account for nearly 27% of the Albumin (Human) Market Share, with over 850 million people affected globally. Albumin is used in dialysis and nephrotic syndrome management, with 45% of severe kidney cases requiring albumin supplementation. Albumin (Human) Market Analysis shows growing demand due to rising chronic kidney disease prevalence.

Neoplasm: Neoplasm applications contribute approximately 25%, with albumin used in oncology drug delivery systems. Around 30% of chemotherapy formulations utilize albumin-based carriers, enhancing drug efficacy. Albumin (Human) Market Insights indicate that cancer incidence exceeds 19 million new cases annually, supporting Albumin (Human) Market Growth and Albumin (Human) Market Opportunities.

Albumin (Human) Market Regional Outlook

Download Free Sample to learn more about this report.

NORTH AMERICA

North America remains the largest contributor to the Albumin (Human) Market, holding approximately 37% share, driven by robust plasma collection infrastructure and advanced healthcare systems. The region accounts for more than 45 million liters of plasma collected annually, with the United States contributing nearly 83% of the regional plasma supply. Albumin (Human) Market Insights show that over 75% of hospitals in North America regularly use albumin, especially in intensive care units, trauma centers, and surgical settings. The Albumin (Human) Market Growth in North America is strongly supported by a high burden of chronic diseases, with over 130 million individuals affected by conditions such as liver cirrhosis, kidney failure, and cardiovascular diseases. Approximately 48% of albumin demand in the region is associated with liver-related treatments, while 32% is linked to critical care applications such as burns and sepsis. Additionally, more than 60% of global plasma fractionation facilities are located in North America, enhancing production capacity and ensuring consistent supply. Albumin (Human) Market Trends indicate that recombinant albumin adoption in North America has increased by nearly 20% over the past 5 years, while investments in plasma collection centers have grown by 30% between 2020 and 2025. The region also leads in clinical research, with over 200 ongoing clinical trials involving albumin-based therapies, reinforcing Albumin (Human) Market Outlook and Albumin (Human) Market Opportunities.

EUROPE

Europe holds approximately 28% of the Albumin (Human) Market Share, supported by strong regulatory frameworks and a well-established healthcare infrastructure. The region collects nearly 21 million liters of plasma annually, with Germany, France, Italy, and the United Kingdom contributing more than 65% of total regional plasma supply. Albumin (Human) Market Analysis shows that over 68% of albumin consumption in Europe occurs in hospitals, particularly in surgical and intensive care settings. The aging population significantly influences Albumin (Human) Market Growth in Europe, with more than 21% of the population aged 65 years and above, leading to increased demand for albumin in managing chronic diseases. Liver disease prevalence in Europe exceeds 30 million cases, contributing to nearly 45% of regional albumin usage. Additionally, kidney-related disorders account for around 28% of albumin demand, while oncology applications contribute approximately 27%. Albumin (Human) Market Trends in Europe show increasing adoption of recombinant albumin, which has grown by approximately 16% in recent years, particularly in pharmaceutical formulations and vaccine production. More than 90% of albumin products in Europe meet stringent safety and quality standards, with compliance processes accounting for nearly 25% of production timelines. The region also invests heavily in plasma fractionation technology, with over 40% of facilities upgraded between 2021 and 2024, strengthening Albumin (Human) Market Outlook and Albumin (Human) Market Insights.

ASIA-PACIFIC

Asia-Pacific represents approximately 29% of the Albumin (Human) Market Size, making it one of the fastest-growing regions in terms of demand and infrastructure expansion. The region has witnessed a 50% increase in plasma collection capacity over the last decade, with China alone accounting for nearly 59% of regional albumin production. India contributes around 21%, while Japan holds approximately 11% share in regional consumption. Albumin (Human) Market Research Report indicates that hospital infrastructure in Asia-Pacific has expanded by over 40% in the past 10 years, with more than 65% of tertiary care hospitals now equipped to administer albumin therapies. The prevalence of liver diseases in the region exceeds 50 million cases, accounting for nearly 46% of albumin usage, while kidney diseases contribute around 26% and oncology applications approximately 28%. Albumin (Human) Market Trends highlight that therapeutic demand has increased by 27% between 2020 and 2025, driven by rising healthcare expenditure and improved access to advanced treatments. Additionally, the number of plasma collection centers has increased by over 45%, supporting supply chain improvements. The adoption of freeze-dried albumin in rural and remote healthcare facilities has grown by 35%, due to longer shelf life and easier storage. Furthermore, Albumin (Human) Market Opportunities in Asia-Pacific are driven by government initiatives, with healthcare spending increasing by 18% annually in several countries. Pharmaceutical applications of albumin have also expanded, with nearly 30% of regional production used in drug formulation, reinforcing Albumin (Human) Market Growth and Albumin (Human) Market Outlook.

MIDDLE EAST & AFRICA

The Middle East & Africa region accounts for approximately 6% of the Albumin (Human) Market Share, with demand steadily increasing due to improving healthcare infrastructure and rising disease burden. The region collects approximately 5 million liters of plasma annually, which fulfills only about 58% of local demand, resulting in significant reliance on imports. Albumin (Human) Market Analysis shows that urban hospitals account for nearly 54% of albumin usage, while rural healthcare facilities contribute around 28%, highlighting uneven distribution. Chronic diseases affect nearly 27% of the regional population, with liver diseases accounting for approximately 40% of albumin demand, kidney disorders contributing 30%, and oncology applications around 30%. Albumin (Human) Market Trends indicate that healthcare investments in the region have increased by 23% over the past 5 years, leading to a 15% rise in hospital capacity and improved access to albumin therapies. Countries such as Saudi Arabia, UAE, South Africa, and Egypt collectively contribute over 65% of regional demand, driven by expanding healthcare infrastructure and increasing adoption of advanced therapies.

List of Top Albumin (Human) Companies

• CSL Behring
• Baxter
• Grifols
• Octapharma
• Zhongsheng Group
• Taibang Bio
• Shanghai Laishi
• Hualan Bio

Top 2 Companies with Highest Market Share

• CSL Behring: holds approximately 18% market share, with operations in over 30 countries and plasma collection exceeding 10 million liters annually.
• Grifols: accounts for nearly 16% market share, operating more than 300 plasma centers worldwide and processing over 15 million liters annually.

Investment Analysis and Opportunities

Albumin (Human) Market Opportunities are expanding due to increased investments in plasma collection infrastructure, with over 400 new plasma centers established globally between 2020 and 2025. Approximately 65% of investments are directed toward fractionation technology upgrades, improving production efficiency by 20%–30%. Albumin (Human) Market Insights show that emerging economies account for nearly 45% of new investment inflows, driven by rising healthcare demand.

Additionally, 50% of leading manufacturers have increased R&D spending to develop recombinant albumin, reducing dependence on human plasma. Albumin (Human) Market Analysis indicates that automation adoption in manufacturing has increased by 35%, enhancing scalability. Strategic partnerships account for 28% of investment activities, supporting Albumin (Human) Market Growth and Albumin (Human) Market Forecast expansion.

New Product Development

New product development in the Albumin (Human) Market focuses on improved safety and extended shelf life, with over 60% of new products incorporating advanced purification technologies. Albumin (Human) Market Trends show that recombinant albumin development has increased by 40%, offering alternatives to plasma-derived products. Approximately 55% of new formulations are designed for oncology drug delivery, enhancing therapeutic outcomes.

Furthermore, manufacturers have introduced high-concentration albumin solutions, increasing efficiency by 25% in clinical applications. Albumin (Human) Market Research Report highlights that more than 30 new product variants were launched globally between 2023 and 2025. Packaging innovations, adopted by 45% of companies, improve storage and reduce contamination risks, supporting Albumin (Human) Market Growth and Albumin (Human) Market Outlook.

Five Recent Developments

• In 2023, over 120 new plasma collection centers were established globally, increasing supply capacity by 18%.
• In 2024, a leading manufacturer improved albumin purification efficiency by 22% through advanced fractionation technology.
• In 2025, recombinant albumin production increased by 35%, reducing reliance on plasma-derived sources.
• Between 2023 and 2024, approximately 40% of companies upgraded manufacturing facilities to meet regulatory standards.
• In 2025, over 25 new albumin-based drug formulations were introduced, expanding therapeutic applications by 30%.

Report Coverage of Albumin (Human) Market

The Albumin (Human) Market Report provides comprehensive coverage of market segmentation, trends, and competitive landscape, analyzing over 50 key market participants globally. The report includes data from more than 30 countries, covering approximately 90% of global albumin consumption. Albumin (Human) Market Analysis evaluates 10+ application areas, including liver, kidney, and oncology treatments, representing over 80% of demand.

Additionally, the report examines production processes across 100+ plasma fractionation facilities, highlighting technological advancements and efficiency improvements of up to 30%. Albumin (Human) Market Insights also include supply chain analysis, covering plasma collection, processing, and distribution stages, which collectively account for 95% of product lifecycle activities. The Albumin (Human) Industry Report further provides detailed regional insights and strategic developments, supporting informed decision-making and Albumin (Human) Market Opportunities identification.